Beth Dudley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Beth Dudley has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Randall E. Brand
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, USA
6 shared publications- Eve Karloski
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, USA
5 shared publications - Bryson William Katona
Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
4 shared publications - Randall E. Brand
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
4 shared publications Elena M. Stoffel
University of Michigan, Ann Arbor, MI, USA
3 shared publicationsFay Kastrinos
Division of Digestive and Liver Diseases Columbia University Irving Medical Center New York New York USA
3 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (5) , 731-737
Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes
- 22 May 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (5) , 731-737
Open AccessCigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes
- 31 January 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (1) , 15
A history of the collaborative group of the Americas on inherited gastrointestinal cancer (CGA-IGC): 1995–2025
The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) was created in 1995, when a small group of clinicians and researchers interested in improving the understanding of hereditary gastrointestinal (GI) cancer syndromes met in St. Louis. The organization was modeled after similar societies being formed internationally, with the goals of addressing uniquely American aspects of the healthcare of patients, providing opportunities for interested institutions and individuals to collaborate on studies, and facilitating affordable and accessible meetings. Over the subsequent 30 years, CGA-IGC has grown in size and scope. The organization was formally established in 1996 and annual academic meetings began in 1997, at which time the organization's name was the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC). Milestones included the organization's first strategic plan in 2010, the hiring of outside administrative management in 2014, and the creation of working committees in 2017. These decisions led to progressive growth of the organization, allowing for provision of year-round educational opportunities and increased member engagement. Given the recognition that the hereditary syndromes of interest to this group involve all parts of the gastrointestinal tract, the organization's name was changed from Collaborative Group of the Americas on Inherited Colorectal Cancer to Collaborative Group of the Americas on Inherited Gastrointestinal Cancer in 2018. Presently, CGA-IGC enjoys record-high membership, with over 500 members. A new 3-year strategic plan was implemented in 2024 to guide CGA-IGC into its next 30 years.
- 31 January 2026
- Published by Springer Nature in Familial Cancer
- Vol. 25 (1) , 15
A history of the collaborative group of the Americas on inherited gastrointestinal cancer (CGA-IGC): 1995–2025
The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) was created in 1995, when a small group of clinicians and researchers interested in improving the understanding of hereditary gastrointestinal (GI) cancer syndromes met in St. Louis. The organization was modeled after similar societies being formed internationally, with the goals of addressing uniquely American aspects of the healthcare of patients, providing opportunities for interested institutions and individuals to collaborate on studies, and facilitating affordable and accessible meetings. Over the subsequent 30 years, CGA-IGC has grown in size and scope. The organization was formally established in 1996 and annual academic meetings began in 1997, at which time the organization's name was the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC). Milestones included the organization's first strategic plan in 2010, the hiring of outside administrative management in 2014, and the creation of working committees in 2017. These decisions led to progressive growth of the organization, allowing for provision of year-round educational opportunities and increased member engagement. Given the recognition that the hereditary syndromes of interest to this group involve all parts of the gastrointestinal tract, the organization's name was changed from Collaborative Group of the Americas on Inherited Colorectal Cancer to Collaborative Group of the Americas on Inherited Gastrointestinal Cancer in 2018. Presently, CGA-IGC enjoys record-high membership, with over 500 members. A new 3-year strategic plan was implemented in 2024 to guide CGA-IGC into its next 30 years.
- Open Access
The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration
Background: Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.Methods: Individuals with PDAC with a germline heterozygous PV/LPV in ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.Results: The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group (p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls (p = .003) but there was no statistical difference when assessing only affected SDRs (p = .344).Conclusions: Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.
Open AccessThe role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration
Background: Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.Methods: Individuals with PDAC with a germline heterozygous PV/LPV in ATM, BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.Results: The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group (p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls (p = .003) but there was no statistical difference when assessing only affected SDRs (p = .344).Conclusions: Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Mo1153 OUTCOMES OF GASTRIC CANCER SURVEILLANCE IN LYNCH SYNDROME
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Mo1153 OUTCOMES OF GASTRIC CANCER SURVEILLANCE IN LYNCH SYNDROME
- Open Access
- 1 January 2023
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 10, 41
Improving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma
Editorial Commentary Improving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma Beth Dudley, Bryson W. Katona
- 1 January 2023
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 10, 41
Open AccessImproving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma
Editorial Commentary Improving uptake of germline genetic testing amongst individuals at high-risk of pancreatic ductal adenocarcinoma Beth Dudley, Bryson W. Katona
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 215
Implementation of a scalable integrative oncology (IO) program in a large community oncology network.
215 Background: Integrative Oncology (IO) has become a specialized area of cancer care because of patient desire for holistic approach to care and in response to unmet symptom burden. Until now most IO programs have been limited to large academic medical centers. At Tennessee Oncology (TO), a large community oncology program spanning over 30 clinical sites of care throughout Tennessee and Georgia, an IO program was developed and implemented to bring IO to patients in the community. Methods: In June 2021, the IO program was launched with a physician and a nurse practitioner, both trained in Integrative Oncology. The program started at 8 clinics with visits primarily performed through telemedicine to allow access to each clinic. Providers were educated via email communication and a short video describing the program. Patient education was provided through our website and flyers placed in clinics. A referral order was created within the electronic health record. Results: Within one year, the IO program grew from seeing less than 20 patients per month to seeing over 100 patients per month. To date we have provided approximately 1,050 IO visits for 432 unique patients. Of these patients, 362 (83%) were female and 70 were male. The average age was 59 years old. The top three associated malignancies for patients were breast (n = 182), colorectal (n = 30), and gynecologic oncology (n = 29). Our IO program has expanded from eight to 16 clinics during this time frame. 75% of visits were provided through telemedicine. The most common reasons for IO referral were nutrition and symptom management (fatigue, neuropathy, etc). Conclusions: Implementation of an IO program is possible and scalable in a large community oncology setting. Future directions include studying the impact of our program on patient experience and overall health and wellness.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 215
Implementation of a scalable integrative oncology (IO) program in a large community oncology network.
215 Background: Integrative Oncology (IO) has become a specialized area of cancer care because of patient desire for holistic approach to care and in response to unmet symptom burden. Until now most IO programs have been limited to large academic medical centers. At Tennessee Oncology (TO), a large community oncology program spanning over 30 clinical sites of care throughout Tennessee and Georgia, an IO program was developed and implemented to bring IO to patients in the community. Methods: In June 2021, the IO program was launched with a physician and a nurse practitioner, both trained in Integrative Oncology. The program started at 8 clinics with visits primarily performed through telemedicine to allow access to each clinic. Providers were educated via email communication and a short video describing the program. Patient education was provided through our website and flyers placed in clinics. A referral order was created within the electronic health record. Results: Within one year, the IO program grew from seeing less than 20 patients per month to seeing over 100 patients per month. To date we have provided approximately 1,050 IO visits for 432 unique patients. Of these patients, 362 (83%) were female and 70 were male. The average age was 59 years old. The top three associated malignancies for patients were breast (n = 182), colorectal (n = 30), and gynecologic oncology (n = 29). Our IO program has expanded from eight to 16 clinics during this time frame. 75% of visits were provided through telemedicine. The most common reasons for IO referral were nutrition and symptom management (fatigue, neuropathy, etc). Conclusions: Implementation of an IO program is possible and scalable in a large community oncology setting. Future directions include studying the impact of our program on patient experience and overall health and wellness.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
896: THE GUT MICROBIOME PREDICTS EARLY-ONSET COLORECTAL CANCER BASED ON KNOWN RISK FACTORS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
896: THE GUT MICROBIOME PREDICTS EARLY-ONSET COLORECTAL CANCER BASED ON KNOWN RISK FACTORS
- Top Cited PapersOpen Access
- 15 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28) , 3257-3266
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
PURPOSE: To report pancreas surveillance outcomes of high-risk individuals within the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of patients enrolled in prior CAPS studies. METHODS: Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. RESULTS: Of 1,461 high-risk individuals enrolled into CAPS5, 48.5% had a pathogenic variant in a PDAC-susceptibility gene. Ten patients were diagnosed with PDAC, one of whom was diagnosed with metastatic PDAC 4 years after dropping out of surveillance. Of the remaining nine, seven (77.8%) had a stage I PDAC (by surgical pathology) detected during surveillance; one had stage II, and one had stage III disease. Seven of these nine patients with PDAC were alive after a median follow-up of 2.6 years. Eight additional patients underwent surgical resection for worrisome lesions; three had high-grade and five had low-grade dysplasia in their resected specimens. In the entire CAPS cohort (CAPS1-5 studies, 1,731 patients), 26 PDAC cases have been diagnosed, 19 within surveillance, 57.9% of whom had stage I and 5.2% had stage IV disease. By contrast, six of the seven PDACs (85.7%) detected outside surveillance were stage IV. Five-year survival to date of the patients with a screen-detected PDAC is 73.3%, and median overall survival is 9.8 years, compared with 1.5 years for patients diagnosed with PDAC outside surveillance (hazard ratio [95% CI]; 0.13 [0.03 to 0.50], P = .003). CONCLUSION: Most pancreatic cancers diagnosed within the CAPS high-risk cohort in the recent years have had stage I disease with long-term survival.
- 15 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28) , 3257-3266
Top Cited PapersOpen AccessThe Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
PURPOSE: To report pancreas surveillance outcomes of high-risk individuals within the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of patients enrolled in prior CAPS studies. METHODS: Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. RESULTS: Of 1,461 high-risk individuals enrolled into CAPS5, 48.5% had a pathogenic variant in a PDAC-susceptibility gene. Ten patients were diagnosed with PDAC, one of whom was diagnosed with metastatic PDAC 4 years after dropping out of surveillance. Of the remaining nine, seven (77.8%) had a stage I PDAC (by surgical pathology) detected during surveillance; one had stage II, and one had stage III disease. Seven of these nine patients with PDAC were alive after a median follow-up of 2.6 years. Eight additional patients underwent surgical resection for worrisome lesions; three had high-grade and five had low-grade dysplasia in their resected specimens. In the entire CAPS cohort (CAPS1-5 studies, 1,731 patients), 26 PDAC cases have been diagnosed, 19 within surveillance, 57.9% of whom had stage I and 5.2% had stage IV disease. By contrast, six of the seven PDACs (85.7%) detected outside surveillance were stage IV. Five-year survival to date of the patients with a screen-detected PDAC is 73.3%, and median overall survival is 9.8 years, compared with 1.5 years for patients diagnosed with PDAC outside surveillance (hazard ratio [95% CI]; 0.13 [0.03 to 0.50], P = .003). CONCLUSION: Most pancreatic cancers diagnosed within the CAPS high-risk cohort in the recent years have had stage I disease with long-term survival.
- 1 September 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (6) , 1048-1051
COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals
- 1 September 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (6) , 1048-1051
COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals
- Open Access
- 23 October 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 14 (2) , 215-222
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant
Juvenile polyposis syndrome (JPS) is a clinically diagnosed hamartomatous polyposis syndrome that increases the risk of gastrointestinal cancer. Approximately 40%–50% of JPS is caused by a germline disease-causing variant (DCV) in the SMAD4 or BMPR1A genes. The aim of this study was to characterize the phenotype of DCV-negative JPS and compare it with DCV-positive JPS. Herein, we analyzed a cohort of 145 individuals with JPS from nine institutions, including both pediatric and adult centers. Data analyzed included age at diagnosis, family history, cancer history, need for colectomy/gastrectomy, and polyp number and location. Compared with DCV-positive JPS, DCV-negative JPS was associated with younger age at diagnosis (P < 0.001), lower likelihood of having a family history of JPS (P < 0.001), and a lower risk of colectomy (P = 0.032). None of the DCV-negative individuals had gastric or duodenal polyps, and polyp burden decreased after the first decade compared with DCV-positive JPS. Subgroup analysis between SMAD4 and BMPR1A carriers showed that SMAD4 carriers were more likely to have a family history of JPS and required gastrectomy. Taken together, these data provide the largest phenotypic characterization of individuals with DCV-negative JPS to date, showing that this group has distinct differences compared with JPS due to a SMAD4 or BMPR1A variant. Better understanding of phenotype and cancer risk associated with JPS both with and without a DCV may ultimately allow for individualized management of polyposis and cancer risk. Prevention Relevance: Juvenile Polyposis Syndrome (JPS) is a gastrointestinal cancer predisposition syndrome requiring lifelong surveillance, however there is limited data comparing individuals with and without a germline disease-causing variant in SMAD4 or BMPR1A. Herein we show that individuals with JPS without an underlying disease-causing variant have distinct phenotypic differences including lack of upper gastrointestinal polyps and lower rates of a family history of JPS, suggesting that a different approach to management may be appropriate in this population.
- 23 October 2020
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 14 (2) , 215-222
Open AccessPhenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant
Juvenile polyposis syndrome (JPS) is a clinically diagnosed hamartomatous polyposis syndrome that increases the risk of gastrointestinal cancer. Approximately 40%–50% of JPS is caused by a germline disease-causing variant (DCV) in the SMAD4 or BMPR1A genes. The aim of this study was to characterize the phenotype of DCV-negative JPS and compare it with DCV-positive JPS. Herein, we analyzed a cohort of 145 individuals with JPS from nine institutions, including both pediatric and adult centers. Data analyzed included age at diagnosis, family history, cancer history, need for colectomy/gastrectomy, and polyp number and location. Compared with DCV-positive JPS, DCV-negative JPS was associated with younger age at diagnosis (P < 0.001), lower likelihood of having a family history of JPS (P < 0.001), and a lower risk of colectomy (P = 0.032). None of the DCV-negative individuals had gastric or duodenal polyps, and polyp burden decreased after the first decade compared with DCV-positive JPS. Subgroup analysis between SMAD4 and BMPR1A carriers showed that SMAD4 carriers were more likely to have a family history of JPS and required gastrectomy. Taken together, these data provide the largest phenotypic characterization of individuals with DCV-negative JPS to date, showing that this group has distinct differences compared with JPS due to a SMAD4 or BMPR1A variant. Better understanding of phenotype and cancer risk associated with JPS both with and without a DCV may ultimately allow for individualized management of polyposis and cancer risk. Prevention Relevance: Juvenile Polyposis Syndrome (JPS) is a gastrointestinal cancer predisposition syndrome requiring lifelong surveillance, however there is limited data comparing individuals with and without a germline disease-causing variant in SMAD4 or BMPR1A. Herein we show that individuals with JPS without an underlying disease-causing variant have distinct phenotypic differences including lack of upper gastrointestinal polyps and lower rates of a family history of JPS, suggesting that a different approach to management may be appropriate in this population.